TECHNETIUM TC-99M SULFUR COLLOID - Generic Drug Details

What are the generic sources for technetium tc-99m sulfur colloid and what is the scope of freedom to operate?

Technetium tc-99m sulfur colloid is the generic ingredient in six branded drugs marketed by Ge Healthcare, Mallinckrodt, Sun Pharm Inds Inc, Jubilant, and Bracco, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for TECHNETIUM TC-99M SULFUR COLLOID

US Patents:	0
Tradenames:	6
Applicants:	5
NDAs:	7
Clinical Trials:	20
DailyMed Link:	TECHNETIUM TC-99M SULFUR COLLOID at DailyMed

Recent Clinical Trials for TECHNETIUM TC-99M SULFUR COLLOID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	PHASE2
National Cancer Institute (NCI)	Early Phase 1
University of Wisconsin, Madison	Early Phase 1

See all TECHNETIUM TC-99M SULFUR COLLOID clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TECHNETIUM TC-99M SULFUR COLLOID

D10AB	Preparations containing sulfur
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

US Patents and Regulatory Information for TECHNETIUM TC-99M SULFUR COLLOID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	TECHNETIUM TC 99M SULFUR COLLOID	technetium tc-99m sulfur colloid	SOLUTION;ORAL	017724-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	TECHNECOLL	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017059-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Inds Inc	AN-SULFUR COLLOID	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017858-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Jubilant	TECHNETIUM TC-99M SULFUR COLLOID KIT	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	213516-001	Nov 9, 2023	AP	RX	No	No
Ge Healthcare	TECHNETIUM TC 99M TSC	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017784-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	TECHNETIUM TC 99M SULFUR COLLOID	technetium tc-99m sulfur colloid	SOLUTION;INJECTION, ORAL	017456-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Technetium Tc-99m Sulfur Colloid Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook

Last updated: September 21, 2026

Technetium Tc-99m sulfur colloid is a mature, low-cost diagnostic radiopharmaceutical with established demand in liver, spleen, bone-marrow, gastric-emptying, lymphatic, and sentinel-node imaging. Its commercial outlook is driven by procedure volume, Mo-99/Tc-99m generator availability, radiopharmacy distribution, and hospital purchasing rather than by patent exclusivity. Public companies generally do not report product-level revenue for sulfur colloid, so the financial trajectory is best assessed through procedure demand and radiopharmaceutical supply conditions.

The product has limited direct patent risk because its core technology and clinical uses date back decades. Generic or multisource competition, short product shelf life, local radiopharmacy logistics, and reimbursement pressure constrain pricing. Growth is likely to remain modest, with periodic supply volatility caused by reactor outages, generator constraints, and manufacturing disruptions.

What is Technetium Tc-99m sulfur colloid used for?

Technetium Tc-99m sulfur colloid is an injectable diagnostic agent prepared by labeling sulfur colloid particles with technetium-99m. After intravenous administration, the particles are removed from the blood primarily by reticuloendothelial cells in the liver, spleen, and bone marrow. After oral administration, the agent can be used for gastric-emptying studies. It also has applications in lymphatic mapping and sentinel lymph-node localization.

Key clinical applications include:

Application	Clinical purpose	Commercial relevance
Liver imaging	Evaluation of hepatic reticuloendothelial function and focal abnormalities	Mature, declining relative share versus cross-sectional imaging
Spleen imaging	Assessment of splenic size, position, or function	Specialized, lower-volume use
Bone-marrow imaging	Evaluation of marrow distribution and selected hematologic conditions	Niche demand
Gastric-emptying studies	Measurement of gastric transit	Stable use in nuclear medicine departments
Lymphatic imaging	Mapping of lymphatic drainage and sentinel nodes	Important surgical and oncology use
Sentinel-node localization	Preoperative identification of draining lymph nodes	Competitive with Tc-99m tilmanocept, blue dyes, and indocyanine green

The short physical half-life of Tc-99m, approximately six hours, permits useful imaging while limiting radiation exposure. It also creates an operational constraint: hospitals and radiopharmacies must coordinate ordering, preparation, quality control, delivery, and administration within a narrow time window (FDA, 2024a).

What is the FDA regulatory status of Technetium Tc-99m sulfur colloid?

Technetium Tc-99m sulfur colloid is an FDA-approved diagnostic radiopharmaceutical supplied as a nonradioactive kit or preparation that is labeled with Tc-99m before use. The finished product is generally distributed through nuclear pharmacies, radiopharmaceutical manufacturers, hospital pharmacies, or specialty distributors.

FDA-approved labeling identifies the product for imaging of the liver, spleen, bone marrow, lymphatic system, and gastric emptying, depending on the specific product and route of administration. Products may differ in vial configuration, particle characteristics, preparation instructions, and approved indications.

What is the Orange Book status of Technetium Tc-99m sulfur colloid?

The product is a mature multisource diagnostic drug rather than a recently launched branded medicine. Public FDA Orange Book records do not identify a current, commercially significant patent barrier comparable to those associated with protected small-molecule brands. The market is therefore primarily governed by FDA approval, manufacturing controls, radioactive-material licensing, distribution capability, and institutional contracts.

The relevant regulatory barriers are operational rather than exclusivity-based:

• FDA-approved drug manufacturing or compounding capability.
• Compliance with current good manufacturing practice requirements.
• Nuclear Regulatory Commission or agreement-state authorization for radioactive materials.
• Validated radiolabeling and quality-control procedures.
• Reliable access to Tc-99m generators or Mo-99-derived supply.
• Cold-chain and time-sensitive delivery infrastructure.

When does Technetium Tc-99m sulfur colloid lose exclusivity?

Core market exclusivity for Technetium Tc-99m sulfur colloid expired many years ago. The active ingredient, diagnostic use, and fundamental sulfur-colloid labeling technology are longstanding. There is no meaningful remaining period of new-drug exclusivity or patent-protected market exclusivity for the established product.

What patents protect Technetium Tc-99m sulfur colloid?

No active patent estate is publicly associated with the basic sulfur-colloid Tc-99m product that would be expected to prevent generic or multisource supply. Any historical patents covering early radiolabeling methods, colloid preparation, or specific diagnostic applications are generally expired or commercially immaterial.

Potentially relevant intellectual-property rights may still arise around:

• New particle-size distributions.
• Proprietary kit designs.
• Automated radiopharmacy preparation systems.
• Specialized delivery devices.
• New imaging protocols.
• Combination products or procedure-specific methods.

These rights would not necessarily block conventional sulfur-colloid products. They could affect a particular formulation, device, or workflow but would not recreate broad exclusivity for the established drug.

How many companies manufacture or distribute Technetium Tc-99m sulfur colloid?

The market has historically included large radiopharmaceutical suppliers, nuclear pharmacies, hospital-based pharmacies, and regional distributors. Product availability can vary by country and by U.S. service region.

Relevant competitive categories include:

Supplier category	Typical role	Competitive advantage
Large radiopharmaceutical manufacturers	Produce kits or finished radiopharmaceutical products	Scale, FDA infrastructure, national contracts
Nuclear pharmacy networks	Prepare and distribute patient-ready doses	Local delivery, hospital relationships
Hospital pharmacies	Prepare doses for internal use	Control over scheduling and local supply
Specialty distributors	Move kits, generators, or ancillary products	Logistics and purchasing integration
Contract manufacturers	Produce or package components	Manufacturing capacity and regulatory expertise

The competitive field is less concentrated at the patient-dose level than the branded drug market. A hospital may purchase a kit from one supplier, obtain Tc-99m from another source, and rely on a local nuclear pharmacy for preparation and delivery.

What drives the market for Technetium Tc-99m sulfur colloid?

Nuclear medicine procedure volume

Demand is tied to the number of diagnostic and surgical procedures requiring Tc-99m sulfur colloid. Growth in oncology imaging, hepatobiliary evaluation, gastric motility testing, and sentinel-node procedures supports demand. Some traditional liver and spleen applications face substitution from ultrasound, CT, MRI, PET, and other nuclear medicine agents.

Tc-99m supply reliability

Tc-99m is produced from Mo-99, which is manufactured primarily in research reactors. The global supply chain has experienced periodic disruptions from reactor shutdowns, target-processing interruptions, transportation problems, and generator shortages. The International Atomic Energy Agency and OECD Nuclear Energy Agency have identified the Mo-99/Tc-99m supply chain as strategically important because of its dependence on a limited number of reactors and processors (OECD Nuclear Energy Agency, 2019).

A supply disruption can reduce sulfur-colloid administrations even when underlying clinical demand is stable. Hospitals commonly prioritize higher-volume or more time-sensitive Tc-99m procedures when generator supply is constrained.

Radiopharmacy logistics

The product’s six-hour physical half-life limits inventory holding. Suppliers cannot rely on conventional pharmaceutical warehousing. Commercial value is created through production scheduling, radiolabeling, route density, delivery timing, and dose utilization.

Unused doses create direct waste. Hospitals therefore favor suppliers that can align delivery with operating-room schedules, imaging appointments, and emergency demand.

Reimbursement and hospital purchasing

Sulfur colloid is usually purchased through institutional budgets or nuclear pharmacy contracts. Pricing pressure is stronger than for protected oncology drugs because the product has no meaningful patent moat and several substitute agents may be available.

Hospitals typically evaluate:

• Per-dose acquisition cost.
• Delivered dose reliability.
• Waste rates.
• Preparation and quality-control burden.
• Delivery coverage.
• Contract terms.
• Product availability during generator shortages.
• Regulatory and technical support.

What is the financial trajectory for Technetium Tc-99m sulfur colloid?

No major manufacturer publicly reports a standalone revenue line for Technetium Tc-99m sulfur colloid. The product is generally included within broader diagnostic radiopharmaceutical, nuclear pharmacy, or hospital-pharmacy revenue.

The likely financial trajectory is:

Period	Market condition	Financial implication
Historical period	Broad use across liver, spleen, marrow, gastric, and lymphatic imaging	Established volume with limited pricing power
Current market	Stable but mature demand; multisource supply	Low unit growth and competitive pricing
Near term	Procedure volumes supported by oncology and sentinel-node use	Modest revenue stability
Disruption years	Reactor, generator, or transportation interruptions	Temporary volume losses and price volatility
Longer term	Substitution in selected imaging uses and continued radiopharmaceutical demand	Flat to low-single-digit nominal growth

Revenue can rise temporarily during supply shortages if spot prices increase, but shortages also reduce completed procedures and can damage customer retention. The more durable financial value lies in radiopharmacy scale and supply reliability rather than in high per-dose margins.

For manufacturers, sulfur colloid is likely to have a portfolio-support role. It can increase the commercial value of an existing nuclear pharmacy network by filling delivery routes and providing a standard product alongside generators, other Tc-99m agents, PET products, and specialty radiopharmaceuticals.

What generic entry risks exist for Technetium Tc-99m sulfur colloid?

Generic entry risk is already realized rather than prospective. The key risks are competitive erosion and product substitution.

Paragraph IV challenges

A conventional Paragraph IV challenge is unlikely to be commercially important because the principal product technology is mature and no current patent barrier appears to protect the basic market. Any challenge would likely target a narrow formulation, manufacturing process, or device patent rather than the established active product.

Biosimilar risk

Biosimilar risk is not applicable. Technetium Tc-99m sulfur colloid is a radiolabeled chemical diagnostic product, not a biologic. Competition proceeds through generic, abbreviated, kit-based, or multisource drug pathways rather than the biosimilar framework.

Generic launch scenarios

A new entrant would face three primary scenarios:

1. Regional launch through a nuclear pharmacy network, competing on service and availability.
2. National kit supply, requiring substantial FDA, manufacturing, and distribution infrastructure.
3. Hospital-based preparation, where regulatory compliance and operational validation are more important than patent clearance.

The principal launch barriers are radioactive-material licensing, access to Tc-99m, qualified personnel, quality-control systems, and delivery logistics. These barriers can protect incumbent market share even when patents do not.

How does sulfur colloid compare with competing lymphatic imaging agents?

Product or technology	Main advantage	Main limitation
Tc-99m sulfur colloid	Low cost, established nuclear medicine workflow, broad availability	Short half-life, particle variability, logistics
Tc-99m tilmanocept	Targeted binding to mannose receptors; approved for lymphatic mapping	Branded-product pricing and narrower use
Blue dyes	Simple surgical visualization	Lower sensitivity and risk of staining or allergic reactions
Indocyanine green	Real-time fluorescence imaging	Requires specialized imaging equipment and limited tissue penetration
Tc-99m nanocolloid products	Established lymphatic mapping in some markets	Geographic availability and regulatory differences

Sulfur colloid remains commercially relevant where hospitals prioritize low acquisition cost and already have gamma-camera or hybrid imaging infrastructure. Branded or technologically differentiated agents can compete when clinical protocols favor targeted nodal uptake, operating-room integration, or improved visualization.

What patent litigation or settlement agreements affect the product?

There is no widely recognized active patent litigation or settlement framework that controls the established U.S. sulfur-colloid market. The product’s litigation exposure is more likely to involve:

• Manufacturing deviations.
• Product shortages.
• Quality-control disputes.
• Medical malpractice related to imaging interpretation.
• Contract and supply disputes.
• Regulatory enforcement involving radiopharmacy operations.

A patent settlement would have limited commercial relevance unless it concerned a new formulation, device, or proprietary use that captured a material share of lymphatic or sentinel-node procedures.

What is the geographic coverage of the sulfur-colloid market?

The product is used in the United States and other countries with established nuclear medicine infrastructure. Geographic performance depends on:

• Local approval of the kit or finished product.
• Reactor and generator access.
• National radiopharmacy density.
• Hospital nuclear medicine capacity.
• Reimbursement for diagnostic procedures.
• Transportation rules for radioactive materials.
• Availability of trained technologists and pharmacists.

The United States has a large commercial radiopharmacy infrastructure, but regional supply can still vary. Europe and other developed markets may use sulfur colloid or related nanocolloid products under different regulatory names and clinical protocols. Emerging markets have lower utilization where nuclear medicine equipment, reimbursement, and radioisotope supply are limited.

How strong is the patent estate for Technetium Tc-99m sulfur colloid?

The patent estate is weak for the legacy product and potentially stronger only for differentiated delivery or imaging technologies. Commercial defensibility rests on execution:

Competitive factor	Importance
Active patent protection	Low
FDA manufacturing compliance	High
Tc-99m access	High
Nuclear pharmacy network	High
Delivery reliability	High
Hospital contracts	High
Product differentiation	Moderate
Brand recognition	Low to moderate
Reimbursement leverage	Moderate

A supplier with dependable generator access, broad delivery coverage, low waste, and strong institutional contracts can outperform a patent-owning competitor. The product is therefore an operations-driven pharmaceutical market.

Key Takeaways

• Technetium Tc-99m sulfur colloid is a mature diagnostic radiopharmaceutical with broad but specialized clinical use.
• Core patent and regulatory exclusivity have expired; current market access is not controlled by a meaningful patent estate.
• Biosimilar risk does not apply because the product is not a biologic.
• Revenue is not generally disclosed as a standalone product category.
• Financial performance depends on nuclear medicine procedure volume, Tc-99m supply, radiopharmacy logistics, and hospital contracts.
• Demand is stable in gastric-emptying, lymphatic, and sentinel-node applications but faces substitution in some liver and spleen imaging uses.
• Manufacturing and radioactive-material licensing create stronger practical barriers than patents.
• Competitive advantage comes from reliable supply, delivery density, low waste, and institutional purchasing relationships.
• The likely long-term trajectory is flat to low-single-digit growth, with temporary volatility during isotope shortages.

FAQs

Is Technetium Tc-99m sulfur colloid a generic drug?

It is a mature multisource diagnostic radiopharmaceutical product. Market competition is primarily generic or kit-based rather than branded.

Does Technetium Tc-99m sulfur colloid have FDA exclusivity?

No meaningful current market exclusivity is associated with the established product. Its commercial position is based on regulatory compliance and supply capability.

Can Technetium Tc-99m sulfur colloid be replaced by Technetium Tc-99m tilmanocept?

Yes, in some lymphatic mapping and sentinel-node procedures. The two products are not identical, and substitution depends on clinical protocol, hospital equipment, physician preference, reimbursement, and product availability.

Why can sulfur-colloid supply be interrupted?

Supply depends on Mo-99 production, Tc-99m generator availability, radiopharmacy preparation, radioactive-material transportation, and time-sensitive delivery. Failure at any stage can affect patient-dose availability.

Is Technetium Tc-99m sulfur colloid commercially attractive for a new manufacturer?

The product can support a broader radiopharmaceutical portfolio, but standalone profitability is constrained by low differentiation, price competition, short shelf life, and substantial manufacturing and distribution requirements.

References

1. Food and Drug Administration. (2024a). Technetium Tc 99m sulfur colloid injection prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. International Atomic Energy Agency. (2023). Molybdenum-99/technetium-99m supply chain and medical radioisotope production. IAEA.

4. Organisation for Economic Co-operation and Development Nuclear Energy Agency. (2019). The supply of medical radioisotopes: An economic diagnosis and possible solutions. OECD Publishing.

5. Society of Nuclear Medicine and Molecular Imaging. (2023). Procedure standards and clinical guidance for technetium-99m radiopharmaceutical imaging. SNMMI.